Atlanta — The Emory Winship Cancer Institute recently made a visible impact at the largest lung cancer meeting in the world — the 13^th World Conference on Lung Cancer, which was held in July in San Francisco.  In addition to scientific presentations on new therapies for lung cancer, seven Emory physician-scientists also served as session chairs, discussants for key presentations and also served on various program committees.

Read the rest of this entry »

LITTLE ROCK – Thoracic surgeon and lung cancer specialist Matthew A. Steliga, M.D., has joined the staff of the University of Arkansas for Medical Sciences (UAMS) as assistant professor in the Division of Cardiothoracic Surgery.

Read the rest of this entry »

BUFFALO, NY – A pioneering surgical technique for lung cancer that allows the direct delivery of chemotherapy has been developed by Todd Demmy, MD, Chair of Thoracic Surgery at Roswell Park Cancer Institute (RPCI), and is reported in the August 2009 issue of the Annals of Thoracic Surgery.

Read the rest of this entry »

Source:
1. New Treatment Strategy Enhances Outcome for Lung Cancer

May 30, 2009

NEW YORK, NY - A new, international study found that the combination of two drugs delays disease progression for patients with advanced non-small cell lung cancer (NSCLC). Results from the Phase III “ATLAS” trial were presented today by Dr. Vincent Miller of Memorial Sloan-Kettering Cancer Center (MSKCC) at the American Society of Clinical Oncology Annual Meeting.

“This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer.”– Vincent A. Miller, MD

The goal of the study was to determine whether adding erlotinib (Tarceva®), a targeted agent, to maintenance therapy with bevacizumab (Avastin®), an agent commonly used as a component of treatment for advanced NSCLC would delay disease progression. Maintenance therapy involves using one or more agents of a chemotherapy regimen, but not the entire regimen, to delay disease progression and possibly improve survival after patients have previously received stronger standard chemotherapy, which can have significant side effects. Read the rest of this entry »